China approves two self-developed COVID-19 drugs


China approves two self-developed COVID-19 drugs

China approved two domestically developed drugs for COVID-19 patients with mild and moderate symptoms, the country’s National Medical Products Administration said on Sunday.

The small-molecule oral drugs, used for treating adult patients with mild to moderate COVID-19 infections, have been declared by Hainan Simcere Pharmaceutical Co., Limited and Shanghai Wangshi Biological Medicine Technology Co., LTD., according to a statement on the administration’s website.

There are more than 600 medications used for colds, Fever and coughs to treat COVID-19 infection in the country’s current medical insurance catalog, according to Huang Xinyu, an official at the National Healthcare Security Administration, at a press conference held on January 11.



Source link

Covid during pregnancies can turn out to be dangerous. Here’s how coronavirus can affect the fetus


 

Covid during pregnancies can turn out to be dangerous. Here’s how coronavirus can affect the fetus

As we continue to discuss about COVID-19 and the symptoms linked to it, much less amount of attention is given to the effects of the Virus on the newborn. Now, a new study has revealed that the Virus can be harmful to the fetus and there is evidence of the Virus in fetal brain tissue in instances of pregnant people passing the infection to their children. Here is all that you need to know.

“While hemorrhages do occasionally occur in developing brains, it is extremely unusual for there to be this many instances within a 21-month period,” says neurobiologist Katie Long from King’s College London in the UK, as reported by Science Alert.

“It is now of the utmost importance that we follow up with children that were prenatally exposed to COVID-19 so that we can establish if there are any long-lasting neurodevelopmental effects.”

For the study, the team examined a total of 661 fetal tissue samples that were collected between July 2020 and April 2022 and they noticed hemorrhages in 26 of them, and surprisingly COVID-19 was present in all of the tissue samples. All the samples were collected from electively terminated pregnancies.

Since coronavirus was confirmed in the fetus tissues, it can be assumed that it was passed to the fetus from the mother. However, whether the hemorrhaging was a direct consequence of the mother’s COVID or the fetus’s infection – or if the relationship involves some unknown factor – isn’t clear.

The study also identified signs of hemorrhaging were from the late first and early second trimester of gestation. This means the fetal brain can be affected at the earliest stages of its development.

“We know that severe viral infection may influence the fetal brain, but this important study is the first to suggest that this may occur in pregnancies affected by COVID infection,” says physiologist Lucilla Poston from King’s College London. Poston was not involved in the study.

“Whatever the cause, a direct effect of the Virus or an indirect consequence of maternal infection, this study highlights the need for pregnant women to be vaccinated against COVID-19, thus avoiding complications for both mother and baby.”

During the study, traces of SARS-CoV-2 were also detected in tissue samples taken from the placenta, amnion, and umbilical cord, suggesting that there’s the potential for further complications to be caused by the presence of COVID-19.



Source link

Exploring bioinformatics approach for evaluating binding affinities of probable COVID-19 therapeutic decoys


In a recent study published in Scientific Reports, researchers developed a computational workflow based on molecular dynamic (MD) simulations and artificial neural network (ANN) to assess the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein receptor-binding domain (RBD)-human angiotensin-converting enzyme 2 (hACE2) binding affinities of SARS-CoV-2 variants.

Background

Studies have reported that S-hACE2 binding interactions facilitate SARS-CoV-2 entry and subsequent replication in the host. Thus, coronavirus disease 2019 (COVID-19) may be prevented by S-ACE2 binding inhibition.

Accordingly, human soluble ACE2 (hsACE2) that binds to SARS-CoV-2 virions before SARS-CoV-2 entry may prevent COVID-19; however, the approach requires optimization and adaptation to novel SARS-CoV-2 variants.
About the study

In the present study, researchers devised a workflow by combining regular methods with point-cloud-based technology to optimize SARS-CoV-2 variant-specific therapeutic decoy development.

MD simulations were performed to identify human angiotensin-converting enzyme 2 amino acid substitutions that reinforce S RBD-hACE2 interactions, for which an ESF (empirical scoring function) in close relation with the LIE (linear interaction energy) technique was used. In vitro SARS-CoV-2-neutralization assays were performed to assess the inhibition of the SARS-CoV-2 wild-type strain and the Beta variant transmission by hACE2 variants that were in linkage with the fragment crystallizable (Fc) region of human immunoglobulin G1 (hACE2-Fc).

A few variants of hACE2-Fc were also expressed in the Nicotiana benthamiana plant for investigating mass-scale production feasibility. Molecular dynamics run data were combined with hACE2 halos and S RBD halos for ANN (artificial neural network) training. The model was used to estimate binding affinities of SARS-CoV-2 S with hACE2 variants based on the S RBD and hACE2 halos. If a new variant emerged, hACE2 variants could be screened rapidly by the artificial neural network and verified by MD simulations so that COVID-19 treatment strategies could be tailored based on the human soluble ACE2 variant having the greatest binding affinity to the novel SARS-CoV-2 strain.

The potential of the system to estimate the effects of S RBD variant mutations for the same hACE2 decoys was assessed using the SARS-CoV-2 Omicron variant’s BA.1 and BA.2 subvariants as examples. All probable hACE2 mutations were screened, and the 300 most promising estimations were validated by MD simulations. In addition to wild-type hACE2, promising variants pf hACE2, with a C-terminal human IgG Fc tag, were expressed in Chinese hamster-ovary (CHO) cells.

SARS-CoV-2 RNA was quantified by quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC) analysis. The SARS-CoV-2 neutralization potential of hACE2 variants expressed in Nicotiana benthamiana plant leaves (hACE2-Fc K31W_NB) was tested using enzyme-linked immunosorbent assays (ELISA). In-silico analyses were performed to evaluate the binding affinities of hACE2 variants with Omicron BA.3, BA.4/5, and Omicron BA.2.75 RBD proteins.

The crystal structure of wild-type SARS-CoV-2 S RBD bound to hACE2 was downloaded from the protein databank (PDB) database. The model-estimated ΔG value was computed based on electrostatic and van der Waals forces. Sequences used for ANN training comprised S RBD sequences (n=1,165) and hACE2 sequences (n=95) retrieved from visual examination, literature search, or the global initiative on sharing all influenza data (GISAID) database by 4 January 2022.
Results

The hACE2- Fc K31W, hACE2 T27Y_L79T_N330Y_K31W, and hACE2 T27Y_ L79T_K31W hACE2 variants were identified as high-binding affinity candidates. Candidates produced in N. benthamiana showed 5.0-fold lower and 6.0-fold lower IC50 (half-maximal inhibitory concentration) values in comparison to the same variant produced in CHO cells and wild-type hACE2-Fc, respectively. The findings indicated that hACE2-Fc variants with correct folding could be produced in N. benthamiana and plant-produced soluble ACE2 variants represent a promising, cost-effective therapeutic option against SARS-CoV-2.

The ESF estimations were validated in vitro by Virus neutralization assays. Experimental data correlated well with estimated ΔGpred (Gibbs free energies) in the model. In comparison to the wild-type of hACE2, the majority of hACE2 variants showed enhanced binding affinities to the SARS-CoV-2 Beta variant, Delta variant, and Omicron’s BA.1 subvariant and BA.2 subvariant. The hACE2-K31W was the only mutant with very less Gibbs free energy, indicating that the K31W mutation may contribute to S RBD interactions. K31W mutation presence was observed in most high-binding affinity mutants.

Variants with 3.0 to 5.0 mutations showed the greatest S RBD binding. The hACE2 T27Y_L79T_K31W and hACE2 T27Y_L79T_N330Y_ K31W showed remarkably high binding affinities for BA.2 S RBD (ΔGpred value −71.0 kJ/mol) in comparison to that for wild-type of hACE2 (−52.0 kJ/mol). With estimated binding affinities of −62.0 and −67.0 kJ/mol, the hACE2 T27Y_L79T_K31W and hACE2 T27Y_L79T_N330Y_K31W variants were the topmost high-affinity variants for BA.3, and the binding affinities for Omicron BA.4/5 and Omicron BA.2.75 were lower. The highest outliers (MD ΔG values of <- 70 kJ/mol) were mapped by the model, to the highest binding affinity value observed.

The findings indicated that ANN was not only able to better estimate values closer to the bulk of the binding affinity distribution than extrapolating from closely related variants but also reliably mapped the high-affinity variants to the highest affinity bracket of −68.0 kJ/mol. The artificial neural network could learn meaningful physical insights from Halos with performance significantly better than simply learning a regression-to-the-mean or copy-function, and the model could combine learned insights from relatively different inputs (distant SARS-CoV-2 sequences). The model identified single mutants comparable to the best hACE2 mutant found in the initial MD runs.

Overall, the study findings highlighted a bioinformatics approach of combining MD simulations, in vitro competitive inhibition assays, live-Virus infection assays, and ANN, for rapid, cost-effective and efficient evaluation of the binding affinity of hACE2 decoys to novel SARS-CoV-2 strains at an initial stage, reducing durations of hACE2- decoy adaptation and sample requirements for in vitro selections.



Source link

What is known about new Covid variant XBB.1.5?


 A new Covid sub-variant is causing some concern in the US, where it is spreading rapidly.

Some cases have also been recorded in the UK, so what do you need to know about XBB.1.5?

What is XBB.1.5?

It is yet another offshoot of the globally-dominant Omicron Covid variant. Omicron has outperformed the earlier Alpha, Beta, Gamma and Delta coronavirus variants since emerging in late 2021.

Omicron has also given rise to many more contagious sub-variants.

Symptoms of XBB.1.5 are thought to be similar to those of previous Omicron strains. Most people experience cold-like symptoms.

Is XBB.1.5 more infectious or dangerous?

XBB.1.5 evolved from XBB, which began circulating in the UK in September 2022.

XBB had a mutation that helped it beat the body’s immune defences, but this same quality also reduced its ability to infect human cells.

Prof Wendy Barclay from Imperial College London said XBB.1.5 has a mutation known as F486P, which restores this ability to bind to cells while continuing to evade immunity. That makes it spread more easily.

She said these evolutionary changes were like “stepping stones”, as the Virus evolves to find new ways of bypassing the body’s defence mechanisms.

The Wellcome Sanger Institute in Cambridge is sequencing at least 5,000 Covid samples a week, as part of continuing efforts to track variants.

The institute’s Dr Ewan Harrison thinks XBB.1.5 probably emerged when someone got infected with two different Omicron types:

“A bit of the genome from one Virus gets joined up with another bit from a second Virus, and they merge, and that goes on to transmit.”

The World Health Organization (WHO) confirmed that XBB.1.5 has a “growth advantage” over other sub-variants seen so far.

But the WHO said there was no indication so far that it was more serious or harmful than previous Omicron variants.

Where is XBB.1.5 spreading?

According to Centers for Disease Control (CDC) estimates, nearly 28% of Covid cases in the US in the first week of January were caused by XBB.1.5

It had previously estimated as many as 40% of cases were XBB.1.5.

However, the revised figure still represents a sharp increase from only 4% of cases at the start of December.

Covid hospital admissions have been rising in recent weeks across the US, and the government has restarted its free testing programme.

US brings back free at-home Covid tests

Could the XBB.1.5 variant take off in the UK?

It looks likely. The UK had five Omicron waves in 2022, and further spikes in cases seem inevitable.

Figures for the week to Saturday 17 December from Wellcome Sanger suggested that one in 25 Covid cases in the UK were XBB.1.5.

But that was based on just nine samples, so we need to wait to get a better picture.

The UK Health Security Agency is due to release a report on variants spreading in the UK next week.

Prof Barclay said she expected more hospitalisations in the UK if the variant takes off here, “as we expect it to do”.

NHS England has said the fears of a “twindemic” of Covid and flu have already been realised, with both viruses putting strain on an already stretched NHS.
Who can get a Covid booster this winter?
How to look after yourself if you get Covid

Are scientists worried about XBB.1.5?

Prof Barclay said she was not especially concerned about the general UK population because there was “no indication” that XBB.1.5 would “break through” the protection against severe illness provided by vaccines.

But she is worried about the potential effect on the vulnerable, including the immunocompromised, who get less benefit from Covid jabs.

Prof David Heymann from the London School of Hygiene and Tropical Medicine acknowledged that there was still a fair amount to learn about this latest variant.

But he said it was unlikely to cause major problems in countries like the UK which have high levels of vaccination and previous infections.

His concern was for countries like China, where there was both low take-up of vaccines and little natural immunity because of prolonged lockdowns.

“China needs to share clinical information on people infected in order to see how the variant behaves in a non-immune population,” Prof Heymann said.
How is China trying to beat its latest Covid surge?

visit: infectious.pencis.com



Source link